IPP Bureau

BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK
BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK

By IPP Bureau - March 21, 2025

PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions

Lucas Meyer Cosmetics introduces GlowCytocin to capture the science of “Love Glow”
Lucas Meyer Cosmetics introduces GlowCytocin to capture the science of “Love Glow”

By IPP Bureau - March 20, 2025

First-of-its-kind active cosmetic ingredient directly activates the oxytocin receptor, mimicking the dermatological effects of being in love

Indegene launches new center in London
Indegene launches new center in London

By IPP Bureau - March 20, 2025

Zota Health Care expands Davaindia network to 1,530 stores
Zota Health Care expands Davaindia network to 1,530 stores

By IPP Bureau - March 20, 2025

The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru

USFDA grants Priority Review for new indication of finerenone for patients with common heart failure
USFDA grants Priority Review for new indication of finerenone for patients with common heart failure

By IPP Bureau - March 20, 2025

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions

By IPP Bureau - March 20, 2025

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L

ZIM Laboratories receives marketing authorization for Dimethyl Fumarate in Portugal
ZIM Laboratories receives marketing authorization for Dimethyl Fumarate in Portugal

By IPP Bureau - March 20, 2025

Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis

Briefs: Dr. Agarwal's Eye Hospital and Apitoria Pharma
Briefs: Dr. Agarwal's Eye Hospital and Apitoria Pharma

By IPP Bureau - March 20, 2025

Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA

Healthcare Triangle appoints Sujatha Ramesh as COO
Healthcare Triangle appoints Sujatha Ramesh as COO

By IPP Bureau - March 20, 2025

Previously, Sujatha has held leadership positions at prominent organizations, including Publicis Sapient, Infinite Computer Solutions, and Capgemini

Entero launches ‘HealthEdge’ programme to empower Retail Chemists
Entero launches ‘HealthEdge’ programme to empower Retail Chemists

By IPP Bureau - March 20, 2025

UFlex’s FlexiTubes to showcase sustainable beauty packaging at COSMOPROF Italy 2025
UFlex’s FlexiTubes to showcase sustainable beauty packaging at COSMOPROF Italy 2025

By IPP Bureau - March 20, 2025

FlexiTubes will showcase range of eco-friendly and innovative tube options

Aerogen opens India HQ in New Delhi
Aerogen opens India HQ in New Delhi

By IPP Bureau - March 20, 2025

The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India

Croda opens advanced lipids manufacturing facility in Pennsylvania
Croda opens advanced lipids manufacturing facility in Pennsylvania

By IPP Bureau - March 19, 2025

This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’

Financial Times names Indegene among high-growth companies in Asia-Pacific 2025
Financial Times names Indegene among high-growth companies in Asia-Pacific 2025

By IPP Bureau - March 19, 2025

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products

Zydus receives final approval from USFDA for Apalutamide Tablets, 60 mg
Zydus receives final approval from USFDA for Apalutamide Tablets, 60 mg

By IPP Bureau - March 19, 2025

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer

Latest Stories

Interviews

Packaging